UA70976C2 - (гетеро)арилбіциклічні гетероарильні похідні, їх одержання та використання як інгібіторів протеаз - Google Patents

(гетеро)арилбіциклічні гетероарильні похідні, їх одержання та використання як інгібіторів протеаз

Info

Publication number
UA70976C2
UA70976C2 UA2001064172A UA01064172A UA70976C2 UA 70976 C2 UA70976 C2 UA 70976C2 UA 2001064172 A UA2001064172 A UA 2001064172A UA 01064172 A UA01064172 A UA 01064172A UA 70976 C2 UA70976 C2 UA 70976C2
Authority
UA
Ukraine
Prior art keywords
arylbicyclic
hetero
preparation
application
compounds
Prior art date
Application number
UA2001064172A
Other languages
English (en)
Russian (ru)
Inventor
Дерін Артур Аллен
Джейсон Хатайє
Вітольд Хрузевіч
Алєксандр Колєсніков
Річард Лоуренс Макман
Рупа Раі
Джефрі Р. Спенсер
Ерік Дж. Вернер
Эрик Дж. ВЕРНЕР
Венді Янг
Вільям Дворак Шредер
Original Assignee
Аксіз Фармасьютікелз, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аксіз Фармасьютікелз, Інк. filed Critical Аксіз Фармасьютікелз, Інк.
Publication of UA70976C2 publication Critical patent/UA70976C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

У цьому винаході запропоновано нові сполуки формули (І): А-В, їх форми проліків або фармацевтично прийнятні їх солі, де А - насичена, ненасичена або частково ненасичена біциклічна гетероциклічна кільцева структура, і В - арильна або гетероарильна група. Кращі сполуки цього винаходу містять бензімідазольне або індольне ядро. Сполуки цього винаходу є інгібіторами серинових протеаз, урокінази (АПу), Фактора Ха (FXa) і/або Фактора VIIa (FVIIa) й використовуються як протипухлинні агенти та/або як антикоагулянти для лікування або запобігання тромбоемболії ссавців.
UA2001064172A 1998-12-18 1999-12-17 (гетеро)арилбіциклічні гетероарильні похідні, їх одержання та використання як інгібіторів протеаз UA70976C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11300798P 1998-12-18 1998-12-18
PCT/US1999/030302 WO2000035886A2 (en) 1998-12-18 1999-12-17 (hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors

Publications (1)

Publication Number Publication Date
UA70976C2 true UA70976C2 (uk) 2004-11-15

Family

ID=22347074

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2001064172A UA70976C2 (uk) 1998-12-18 1999-12-17 (гетеро)арилбіциклічні гетероарильні похідні, їх одержання та використання як інгібіторів протеаз

Country Status (20)

Country Link
US (1) US6867200B1 (uk)
EP (1) EP1140859A2 (uk)
JP (1) JP2002532479A (uk)
KR (1) KR20010086119A (uk)
CN (1) CN1344256A (uk)
AU (1) AU779117B2 (uk)
BR (1) BR9916363A (uk)
CA (1) CA2355249A1 (uk)
CZ (1) CZ20012006A3 (uk)
EA (1) EA200100675A1 (uk)
EE (1) EE200100323A (uk)
HU (1) HUP0104987A3 (uk)
IL (1) IL143801A0 (uk)
NO (1) NO20012980L (uk)
NZ (1) NZ512375A (uk)
PL (1) PL349192A1 (uk)
SK (1) SK7972001A3 (uk)
TR (1) TR200102533T2 (uk)
UA (1) UA70976C2 (uk)
WO (1) WO2000035886A2 (uk)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE362468T1 (de) * 2000-07-25 2007-06-15 Merck & Co Inc N-substituierte indole mit anwendung in der behandlung von diabetes
US6465503B2 (en) * 2000-08-11 2002-10-15 Axys Pharmaceuticals, Inc. Selective urokinase inhibitors
EP1364960A4 (en) 2001-02-02 2005-05-18 Chugai Pharmaceutical Co Ltd PEPTIDE DERIVATIVES
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
JP2004535411A (ja) 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物
WO2003006670A2 (en) * 2001-07-09 2003-01-23 Axys Pharmaceuticals, Inc. 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
NZ530580A (en) 2001-07-27 2007-02-23 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6825208B2 (en) 2001-08-20 2004-11-30 Bristol-Myers Squibb Pharma Company Tetrahydroquinoline derivatives as antithrombotic agents
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
US20050203094A1 (en) * 2002-02-13 2005-09-15 Aleksandr Kolesnikov 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors
US6867320B2 (en) 2002-02-21 2005-03-15 Asahi Kasei Pharma Corporation Substituted phenylalkanoic acid derivatives and use thereof
CN101172983A (zh) 2002-03-20 2008-05-07 麦它波莱克斯股份有限公司 取代的苯乙酸
JP4334476B2 (ja) * 2002-07-29 2009-09-30 株式会社静岡カフェイン工業所 １，３アゾール誘導体及び同誘導体を含む血栓症治療のための医薬組成物
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
CN100457730C (zh) 2002-08-29 2009-02-04 默克公司 具有抗糖尿病活性的吲哚化合物
PT1569912E (pt) 2002-12-03 2015-09-15 Pharmacyclics Llc Derivados 2-(2-hidroxibifenil-3-il)-1h-benzoimidazole-5- carboxamidina como inibidores do fator viia
AU2003300106A1 (en) * 2003-01-08 2004-08-10 Axys Pharmaceuticals, Inc. 2-'5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl!- carboxylic acid derivatives as factor viia inhibitors
NZ540612A (en) 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US7199259B2 (en) 2003-06-20 2007-04-03 Metabolex, Inc. Resolution of α-(phenoxy)phenylacetic acid derivatives
US7470807B2 (en) 2003-08-14 2008-12-30 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivatives and use thereof
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
JP2008500357A (ja) 2004-05-25 2008-01-10 メタボレックス インコーポレーティッド Ｐｐａｒのモジュレーターとしての置換されたトリアゾールおよびこれらの調製方法
EP1751114A2 (en) * 2004-06-02 2007-02-14 Pharmacyclics, Inc. Factor viia inhibitor
EP1761504A2 (en) * 2004-06-02 2007-03-14 Pharmacyclics, Inc. Factor viia inhibitor
US8729117B2 (en) 2004-06-02 2014-05-20 Pharmacyclics, Inc. Factor VIIa inhibitor
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
ES2402362T3 (es) * 2004-09-30 2013-05-03 Takeda Pharmaceutical Company Limited Inhibidores de la bomba de protones
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
US7714131B2 (en) 2005-09-23 2010-05-11 Metabolex, Inc. Process for the stereoselective preparation of (−)-halofenate and derivatives thereof
WO2007056155A1 (en) * 2005-11-03 2007-05-18 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
CA2647811A1 (en) 2006-03-30 2007-10-11 Asahi Kasei Pharma Corporation Substituted bicyclic derivative and use thereof
ES2422603T3 (es) 2007-05-31 2013-09-12 Shionogi & Co Compuestos oxiimino y el uso de estos
US20100216021A1 (en) * 2007-06-19 2010-08-26 Rhodri Evans Electrode plate
CA2702970A1 (en) 2007-10-16 2009-04-23 Pharmacyclics, Inc. Manufacture, compositions and uses of coagulation factor viia modulator
CN102015656A (zh) 2008-04-28 2011-04-13 旭化成制药株式会社 苯丙酸衍生物及其用途
WO2009151152A1 (en) 2008-06-11 2009-12-17 Shionogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
CN101654427B (zh) * 2008-08-19 2012-12-05 信谊药厂 抗凝化合物、组合物及其用途
KR101354418B1 (ko) * 2009-07-30 2014-01-23 단국대학교 산학협력단 형광 탐지자 및 이의 제조 방법
EP2619198A1 (en) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI527814B (zh) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI541241B (zh) * 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
WO2012149049A1 (en) * 2011-04-26 2012-11-01 Indiana University Research And Technology Corporation Tyrosine phosphatase inhibitors and uses thereof to modulate the activity of enzymes involved in the pathology of mycobacterium tuberculosis
KR102092612B1 (ko) 2012-06-15 2020-03-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 호흡기 합포체 바이러스의 항바이러스제로서의 헤테로사이클로 치환된 1,3-디하이드로-2h-벤즈이미다졸-2-온 유도체
EP2977374A1 (en) * 2014-07-21 2016-01-27 Université de Strasbourg Molecules presenting dual emission properties
EP3201292B1 (en) * 2014-09-30 2018-08-01 Transitions Optical, Inc. Ultraviolet light absorbers
EP4445956A2 (en) 2015-01-06 2024-10-16 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
JP6986972B2 (ja) 2015-06-18 2021-12-22 エイティナイン バイオ リミテッド 置換４−ベンジル及び４−ベンゾイルピペリジン誘導体
ES2821049T3 (es) 2015-06-18 2021-04-23 89Bio Ltd Derivados de piperidina 1,4 sustituidos
WO2016209809A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
KR102547771B1 (ko) * 2015-11-09 2023-06-26 고려대학교 산학협력단 4-치환된-2-(5-치환된-1h-인돌-2-일)페놀 유도체, 그 제조방법 및 이를 포함하는 세포 증식 및 전이 억제용 약학 조성물
LT3377488T (lt) 2015-11-19 2023-01-10 Incyte Corporation Heterocikliniai junginiai, kaip imunomoduliatoriai
SI3394033T1 (sl) 2015-12-22 2021-03-31 Incyte Corporation Heterociklične spojine kot imunomodulatorji
MA44860A (fr) * 2016-05-06 2019-03-13 Incyte Holdings Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
CN105884673B (zh) * 2016-06-03 2018-05-11 温州大学 一种吲哚衍生物的合成方法
EP4137489A1 (en) 2016-06-20 2023-02-22 Incyte Corporation Heterocyclic compounds as immunomodulators
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3490983B1 (en) 2016-07-30 2021-02-17 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
JP7028861B2 (ja) 2016-09-09 2022-03-02 ブリストル－マイヤーズ スクイブ カンパニー ピリジル置換のインドール化合物
MX2019007416A (es) 2016-12-22 2019-12-11 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
TWI798192B (zh) 2016-12-22 2023-04-11 美商英塞特公司 免疫調節劑化合物及使用方法
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CN110997670B (zh) 2017-08-04 2022-11-01 百时美施贵宝公司 [1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物
WO2019028302A1 (en) 2017-08-04 2019-02-07 Bristol-Myers Squibb Company SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR7 / 8/9 INHIBITORS
WO2019099336A1 (en) 2017-11-14 2019-05-23 Bristol-Myers Squibb Company Substituted indole compounds
KR20200100687A (ko) 2017-12-15 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 에테르 화합물
AR113959A1 (es) 2017-12-18 2020-07-01 Bristol Myers Squibb Co Compuestos de 4-azaindol
ES2932361T3 (es) 2017-12-19 2023-01-18 Bristol Myers Squibb Co Compuestos de indol sustituidos útiles como inhibidores de TLR
EA202091508A1 (ru) 2017-12-19 2020-09-14 Бристол-Маерс Сквибб Компани 6-азаиндольные соединения
KR20200101398A (ko) 2017-12-19 2020-08-27 브리스톨-마이어스 스큅 컴퍼니 Tlr 억제제로서 유용한 아미드 치환된 인돌 화합물
CA3086431A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Amino indole compounds useful as tlr inhibitors
MX2020006014A (es) 2017-12-20 2020-08-17 Bristol Myers Squibb Co Compuestos de diazaindol.
CN111491918B (zh) 2017-12-20 2023-10-24 百时美施贵宝公司 芳基和杂芳基取代的吲哚化合物
ES2940750T3 (es) 2018-03-30 2023-05-11 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
HRP20230306T1 (hr) 2018-05-11 2023-05-12 Incyte Corporation Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori
JP2022513310A (ja) * 2018-10-02 2022-02-07 ディスク・メディスン，インコーポレイテッド マトリプターゼ２阻害剤及びその使用
CN112912382B (zh) 2018-10-24 2024-07-02 百时美施贵宝公司 经取代的吲哚二聚体化合物
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
TW202126652A (zh) 2019-09-30 2021-07-16 美商英塞特公司 作為免疫調節劑之吡啶并［３，２—ｄ］嘧啶化合物
KR20220101664A (ko) 2019-11-11 2022-07-19 인사이트 코포레이션 Pd-1/pd-l1 억제제의 염 및 결정질 형태
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
CN117430525A (zh) * 2023-03-01 2024-01-23 中化学科学技术研究有限公司 席夫碱配体及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2273841A1 (fr) * 1974-06-05 1976-01-02 Labaz Nouveaux stabilisants des polymeres et copolymeres du chlorure de vinyle
CH618639A5 (uk) * 1976-06-04 1980-08-15 Ciba Geigy Ag
DE3224512A1 (de) 1982-07-01 1984-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4623379A (en) * 1984-12-14 1986-11-18 Fmc Corporation Plant growth and development modification using 2-(2-oxycarbonylphenyl)benzimidazole derivatives
JPS63166588A (ja) * 1986-12-27 1988-07-09 Kanzaki Paper Mfg Co Ltd クロメノ化合物およびクロメノ化合物を用いた感熱記録体
JP2869561B2 (ja) * 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
PT95899A (pt) * 1989-11-17 1991-09-13 Glaxo Group Ltd Processo para a preparacao de derivados indole
US6255091B1 (en) * 1995-04-28 2001-07-03 Axys Pharmaceuticals, Inc. Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions
US5942532A (en) * 1997-09-05 1999-08-24 Ortho Pharmaceutical Corporation 2-substituted phenyl-benzimidazole antibacterial agents
AU1608399A (en) 1997-11-26 1999-06-15 Axys Pharmaceuticals, Inc. Substituted amidinoaryl derivatives and their use as anticoagulants
US6150379A (en) 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants

Also Published As

Publication number Publication date
HUP0104987A3 (en) 2002-09-30
EE200100323A (et) 2002-08-15
PL349192A1 (en) 2002-07-01
SK7972001A3 (en) 2002-06-04
IL143801A0 (en) 2002-04-21
KR20010086119A (ko) 2001-09-07
BR9916363A (pt) 2001-12-11
TR200102533T2 (tr) 2006-06-21
AU2711500A (en) 2000-07-03
EP1140859A2 (en) 2001-10-10
HUP0104987A2 (hu) 2002-07-29
NO20012980D0 (no) 2001-06-15
JP2002532479A (ja) 2002-10-02
WO2000035886A2 (en) 2000-06-22
CA2355249A1 (en) 2000-06-22
US6867200B1 (en) 2005-03-15
CZ20012006A3 (cs) 2002-03-13
NO20012980L (no) 2001-08-01
WO2000035886A3 (en) 2000-10-26
CN1344256A (zh) 2002-04-10
AU779117B2 (en) 2005-01-06
NZ512375A (en) 2003-11-28
EA200100675A1 (ru) 2001-12-24

Similar Documents

Publication Publication Date Title
UA70976C2 (uk) (гетеро)арилбіциклічні гетероарильні похідні, їх одержання та використання як інгібіторів протеаз
GEP20074098B (en) Lactam-containing compounds and derivatives thereof as factor xa inhibitors
WO2001044172A8 (en) Salicylamides as serine protease and factor xa inhibitors
EA200100972A1 (ru) Новые соединения и композиции как ингибиторы протеаз
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
WO2004041776A3 (en) SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS
EP1248612A4 (en) NEW SUBSTANCES AND COMPOUNDS AS PROTEASE INHIBITORS
WO2002000651A3 (en) Factor xa inhibitors
NO20082389L (no) 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
ATE268766T1 (de) Stickstoff enthaltende heterobicyclen als factor xa inhibitoren
NO20032801L (no) Tiazolderivater for behandling av PPAR-relaterte forstyrrelser
NZ514981A (en) Renin inhibitors
HUP0203130A2 (hu) Hexahidrofuro[2,3-b]furán-3-il-N-{3-(1,3-benzodioxol-5-il-szulfonil)-(izobutil)-amino-1-benzil-2-(hidroxi-propil)}-karbamát mint retrovírus-proteáz-gátló
GEP20094638B (en) Benzimidazolone carboxylic acid derivatives
WO2006047528A3 (en) Pyrazolobenzamides and derivatives as factor xa inhibitors
ATE223408T1 (de) Heteroaryl-amidinen,-methylamidinen und - guanidinen als protease inhibitoren, insbesondere als urokinase inhibitoren
NO20062599L (no) Fremgangsmate for syntese av perindopril og farmasoytisk akseptable salter derav
NO983992L (no) Serinprotease inhibitorer
WO2002080853A3 (en) Fused heterocyclic inhibitors of factor xa
TR200102524T2 (tr) Dihetero sübstitüe edilmiş metaloproteaz inhibitörleri.
BG105866A (en) Heteroaryl amidines, methylamidines and guanidines as protease inhibitors
TR200101779T2 (tr) Yeni bisiklik bileşenler
WO2002037937A3 (en) Acid derivatives useful as serine protease inhibitors
YU7191A (sh) Oralno aktivni inhibitori renina
ATE247964T1 (de) Als inhibitoren der aicarftnützliche verbindungen